Assertio Holdings, Inc. filings document formal disclosures for a Nasdaq-listed commercial pharmaceutical company, including material-event reports, annual meeting voting results, governance actions, and capital-structure matters. The record includes disclosures on common stock, convertible senior notes, tender-offer communications, and amendments to equity incentive plan provisions.
Assertio's SEC reports also cover material definitive agreements and completed asset-sale disclosures involving branded products such as INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR, and OTREXUP. These filings describe transaction documents, Regulation FD communications, shareholder approvals, executive-compensation plan matters, and operating subjects tied to the company's pharmaceutical commercialization business.
Assertio Holdings, Inc. reported that Brendan P. O’Grady, its former Chief Executive Officer, has resigned from the Company’s Board of Directors. The resignation became effective on the effective date of a waiver and release agreement he executed on November 17, 2025.
The waiver and release agreement was substantially in the form included with Mr. O’Grady’s existing Management Continuity Agreement, previously filed as an exhibit to a Form 10-Q. This filing focuses solely on documenting his board resignation and related contractual step.
Assertio Holdings (ASRT) reported insider equity awards on a Form 4 for CEO and Director Mark L. Reisenauer dated 11/13/2025. The filing shows 500,000 restricted stock units and 1,000,000 stock options granted.
The options carry a $0.8248 exercise price and expire on 11/13/2035. RSUs are tied to one share each and carry an end date of 11/13/2028. Both awards vest in three equal installments on each of the first three anniversaries of the grant date, contingent on continued employment. The grants were awarded for no cash consideration.
Assertio Holdings (ASRT): A company director reported an open‑market sale of 8,959 shares of common stock on 11/10/2025 at a $0.7597 weighted average price. The sale was made under a Rule 10b5‑1 trading plan adopted on November 22, 2024. Following the transaction, the director reported 98,541 shares beneficially owned, held directly. The trade included multiple executions between $0.7544 and $0.7668 per share.
Assertio Holdings (ASRT) reported stronger Q3 2025 results, with total revenue of $49.5 million, up from $29.2 million a year ago, and net income of $11.4 million versus a prior-year loss. Diluted EPS was $0.11. Growth was led by ROLVEDON product sales of $38.6 million in the quarter.
Management noted that Q3 included large distributor purchases of ROLVEDON to support integration into Assertio Specialty, accompanied by higher discounts and extended payment terms. The company anticipates no material net product sales of ROLVEDON in Q4 2025 and Q1 2026, with regular sales of newly labeled product expected to begin in Q2 2026.
For the nine months, revenue was $105.2 million and net loss was $18.4 million, reflecting an $8.2 million loss on the Assertio Therapeutics divestiture and portfolio actions. Cash and cash equivalents were $38.5 million and short-term investments were $54.9 million as of September 30, 2025; accounts receivable rose to $141.3 million and accrued rebates/returns/discounts to $130.5 million tied to Q3 sales terms. The company recorded a $1.7 million SPRIX intangible impairment and revised SPRIX’s remaining life to one year. Long-term debt consisted of $40.0 million principal of 6.5% convertible notes due 2027. Shares outstanding were 96,252,087 as of November 6, 2025.
Assertio Holdings (ASRT) reported two updates. The company furnished a press release announcing financial results for the three and nine months ended September 30, 2025, and named Paul Schwichtenberg as President and Chief Operating Officer, effective November 3, 2025. Schwichtenberg previously served as Chief Transformation Officer. The press release was filed as Exhibit 99.1 and the Item 2.02 information was furnished, not filed.
Assertio Holdings announced a leadership change. Effective October 27, 2025, Brendan O’Grady separated from service as Chief Executive Officer under an “Other Involuntary Termination” per his Management Continuity Agreement. The Board appointed director Mark Reisenauer as Chief Executive Officer, and he will continue to serve on the Board.
Under his offer letter, Reisenauer will receive a base salary of $800,000 per year and an annual target cash bonus opportunity of 85% of base salary, though he will not be eligible for a cash bonus for the remainder of 2025. He will be granted an option to purchase 1,000,000 shares and 500,000 RSUs, each vesting one-third annually over three years under the company’s 2014 Omnibus Incentive Plan. His Management Continuity Agreement provides change-in-control protections, including cash severance equal to two times base salary and two times target bonus, up to 24 months of paid health benefits, accelerated vesting of unvested equity, and outplacement services; outside a change-in-control period, severance includes 18 months of salary continuation, paid health benefits for up to 18 months, earned but unpaid prior-year bonus, and limited outplacement.
Assertio Holdings, through its subsidiary Spectrum Pharmaceuticals, amended and restated its supply agreement with Hanmi Pharmaceutical for the ROLVEDON drug substance. The change, effective after the fixed pricing provisions expire in October 2025, sets long‑term pricing that includes a mid‑single digit percentage reduction to the price agreed after Assertio acquired Spectrum in 2023.
The new price remains fixed for the rest of Spectrum’s license term with Hanmi, while allowing Hanmi to request price increases for periods beginning January 1, 2028 if its costs rise above a set threshold. The amendment also adds a volume-based feature that reduces per‑gram pricing in years when the prior year’s global market volume passes a specified level. Spectrum must provide annual purchase forecasts, and at least fifty percent of forecasted orders must be binding, though there are no minimum purchase requirements. Other supply terms were not materially changed.
Assertio Holdings (ASRT) reported lower revenue and wider losses for the quarter and first half of 2025 while taking strategic steps to simplify the business. Total revenues were $29.2 million for the three months and $55.7 million for the six months ended June 30, 2025, down from $31.1 million and $63.6 million a year earlier, respectively, driven by lower INDOCIN sales despite higher ROLVEDON sales of $16.1 million in the quarter. Cost pressures included higher amortization of intangibles of $9.2 million in the quarter.
The company recorded a net loss of $16.4 million ($0.17 per share) for the quarter and $29.9 million ($0.31 per share) for the six months, which includes an $8.2 million loss on the divestiture of Assertio Therapeutics. Total assets declined to $273.8 million and shareholders' equity fell to $93.3 million. Cash and cash equivalents were $47.1 million with short-term investments of $51.1 million.
Material operational items: the Therapeutics divestiture removed Assertio from opioid-related litigation exposure but produced an $8.2 million loss; the company ceased commercialization of Otrexup (incurring $3.8 million of related costs); management recorded a $16.0 million accrual related to the Luo settlement with corresponding insurance recoverable that was later settled and reduced to zero. The company maintains $39.0 million of 6.5% convertible notes due 2027 and a full valuation allowance on deferred tax assets.
Assertio Holdings, Inc. filed a Form 8-K to report that it released its latest earnings information. On August 11, 2025, the company issued a press release announcing its financial results for the three- and six-month periods ended June 30, 2025, and furnished that release as an exhibit.
The press release is included as Exhibit 99.1, while the cover page interactive data file is provided as Exhibit 104. The company notes that the earnings information in this report is being furnished rather than filed, which affects how it is treated under securities laws and in other future SEC filings.